
Predicta Biosciences is a precision oncology company specializing in comprehensive molecular diagnostics and therapeutics for hematological malignancies, particularly multiple myeloma. Their flagship product, GenoPredicta, uses whole genome sequencing (WGS) on bone marrow biopsies and circulating tumor cells from blood to provide detailed genomic insights that surpass traditional FISH testing. This technology enables accurate diagnosis, prognostic risk assessment, and therapeutic guidance, including detection of resistance mechanisms to immunotherapies. The company integrates AI and multiomic data analysis to discover novel therapeutic targets and improve patient outcomes. Predicta's approach reduces the need for invasive biopsies by enabling blood-based monitoring and supports personalized treatment decisions. Their platform is backed by leading cancer researchers and life sciences investors, positioning them as a transformative player in blood cancer diagnostics and treatment.

Predicta Biosciences is a precision oncology company specializing in comprehensive molecular diagnostics and therapeutics for hematological malignancies, particularly multiple myeloma. Their flagship product, GenoPredicta, uses whole genome sequencing (WGS) on bone marrow biopsies and circulating tumor cells from blood to provide detailed genomic insights that surpass traditional FISH testing. This technology enables accurate diagnosis, prognostic risk assessment, and therapeutic guidance, including detection of resistance mechanisms to immunotherapies. The company integrates AI and multiomic data analysis to discover novel therapeutic targets and improve patient outcomes. Predicta's approach reduces the need for invasive biopsies by enabling blood-based monitoring and supports personalized treatment decisions. Their platform is backed by leading cancer researchers and life sciences investors, positioning them as a transformative player in blood cancer diagnostics and treatment.
Focus: Precision oncology diagnostics and therapeutics for hematological malignancies (notably multiple myeloma)
Flagship product: GenoPredicta — WGS-based cellular liquid biopsy (bone marrow + circulating tumor cells)
Founded: 2023
Headquarters: Boston
Recent funding: Reported Series A (Oct 2025) and prior Seed (Jul 2024); total funding reported ~$28.6M
Diagnostics and therapeutic discovery for hematological malignancies, with emphasis on multiple myeloma
2023
Biotechnology Research
Seed round reported July 16, 2024
23400000
Series A reported Oct 2025 (aggregate Series A amount reported as ~$23.4M)
“Backed by life sciences and strategic investors including Illumina Ventures, Engine Ventures, Binney Street Capital, Mass General Brigham Ventures, Lightchain Capital, BrightEdge (American Cancer Society), and others”
| Company |
|---|
Predicta Biosciences is a precision oncology company that integrates cutting-edge multiomics and liquid biopsies to create innovative diagnostic and therapeutic products. By eliminating the need for invasive bone-marrow biopsies and using small blood-based samples, Predicta enhances immunotherapy treatment decision-making. Additionally, Predicta has developed an in-house therapeutic pipeline focused on novel immunotherapy targets in pre-clinical discovery and development.
We are seeking a highly motivated Senior R&D Scientist to lead assay development efforts focused on NGS technologies, including single-cell RNA-seq and whole genome sequencing. The ideal candidate should have a strong technical background in molecular biology and genomics, and experience developing highly robust and reproducible assays deployed in clinical or research settings. This individual will play a key role in developing assays for the characterization of immune function, translating early research concepts into clinical assays. A strong understanding of immunology and immune-cell biology will therefore be highly beneficial. This laboratory-based scientist should be passionate about developing cutting-edge genomic assays and will work closely with an inter-disciplinary and cross-functional team of other laboratory-based scientists and computational biologists, focused on improving blood-based cancer diagnostic capabilities in areas including cancer detection, measurable residual disease, and other related applications.
Key responsibilities
Experience needed
Preferred qualifications
Work Location
This role is based in Cambridge, MA and is an full time in-office role. Travel or potential relocation to North Carolina in the future may be required.
Why Join Predicta Biosciences?
This is a unique opportunity to be part of a mission-driven team advancing precision diagnostics for hematologic cancers. You’ll play a key role in shaping the quality and performance of our clinical testing efforts and contribute directly to patient-impactful innovations.
The annual salary range for this position is $120,000 - $180,000 plus a 10% bonus opportunity. Predicta considers a variety of factors when determining base compensation, including experience, skills, education, qualifications, and geographic location. Actual compensation will vary, and it is not typical to be hired at or near the top of the range for the role. Additional rewards include equity, flexible time off, 401k Plan, medical, dental and vision plans that are 90% paid by Predicta and a partially company funded HSA.